BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
Fish and Richardson
US Army
Cantor Fitzgerald

Generated: November 18, 2017

DrugPatentWatch Database Preview

Details for Patent: 4,861,760

« Back to Dashboard

Summary for Patent: 4,861,760

Title: Ophthalmological composition of the type which undergoes liquid-gel phase transition
Abstract:The present invention relates to a pharmaceutical composition intended for contacting with a physiological liquid characterized in that said composition is intended to be administered as a non-gelled liquid form and is intended to gel in situ, this composition containing at least one polysaccharide in aqueous solution, of the type which undergoes liquid-gel phase transition gelling in situ under the effect of an increase in the ionic strength of said physiological liquid.
Inventor(s): Mazuel; Claude (Riom, FR), Friteyre; Marie-Claire (Riom, FR)
Assignee: Merck & Co., Inc. (Rahway, NJ)
Application Number:06/911,606
Patent Claim Types:
see list of patent claims

No matches for this query

Foreign Priority and PCT Information for Patent: 4,861,760

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
France85 14689Oct 03, 1985

International Patent Family for Patent: 4,861,760

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Denmark170500► Subscribe
European Patent Office0227494► Subscribe95C0013Belgium► Subscribe
France2588189► Subscribe
Greece862444► Subscribe
Finland91217► Subscribe
Finland863990► Subscribe
Spain2002401► Subscribe
Denmark469886► Subscribe
Cyprus1779► Subscribe
China1046094► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Fish and Richardson
Johnson and Johnson
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

Google Plus